Literature DB >> 9575196

Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes.

M Matsumoto1, M Nishiguchi, S Kikkawa, H Nishimura, S Nagasawa, T Seya.   

Abstract

Human malignant cells are targeted by homologous complement C3b if they express M161Ag, a 43-kDa protein with C3-activating property. cDNA of M161Ag cloned from human leukemia cell lines predicted M161Ag as a novel secretory protein comprised of 428 amino acids including 5 amino acids encoded by TGA codons (Matsumoto M., Takeda, J., Inoue, N., Hara, T., Hatanaka, M., Takahashi, K., Nagasawa, S., Akedo, H., and Seya, T. (1997) Nat. Med. 3, 1266-1270), although the origin of this gene was obscure. Here we clarified this point through genomic and biochemical analysis: 1) 5'-UT and genomic sequences represented the prokaryote promoter and ribosomal binding site; 2) the TGA codons in M161Ag cDNA were translated not into selenocysteines but into tryptophans; 3) M161Ag anchored onto the membrane secondary to its N-terminal palmitoylation like prokaryote lipoproteins; 4) genomic and cDNA clones of M161Ag were highly homologous to Mycoplasma fermentans gene encoding P48, a monocytic differentiation/activation factor, recently released in the data base, although the resultant proteins were different in the amino acid sequences. Additionally, purified soluble M161Ag efficiently provoked IL-1beta, tumor necrosis factor alpha, and IL-6 like P48, and further IL-10 and IL-12 in human peripheral blood monocytes. Thus, M161Ag originates from M. fermentans, and latently infected M. fermentans allows human cells to produce M161Ag. The liberated protein serves as a potent modulator of innate and cellular immune responses via its complement-activating and cytokine-producing activities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575196     DOI: 10.1074/jbc.273.20.12407

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  P48 major surface antigen of Mycoplasma agalactiae is homologous to a malp product of Mycoplasma fermentans and belongs to a selected family of bacterial lipoproteins.

Authors:  S Rosati; S Pozzi; P Robino; B Montinaro; A Conti; M Fadda; M Pittau
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines.

Authors:  M Kurita; M Matsumoto; S Tsuji; M Kawakami; Y Suzuki; H Hayashi; K Toyoshima; T Seya
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

3.  Complement activation in Mycoplasma fermentans-induced mycoplasma clearance from infected cells: probing of the organism with monoclonal antibodies against M161Ag.

Authors:  S Kikkawa; M Matsumoto; T Sasaki; M Nishiguchi; K Tanaka; K Toyoshima; T Seya
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans.

Authors:  Kelley L Davis; Kim S Wise
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice.

Authors:  U Deiters; P F Mühlradt
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Jun Yang; W Craig Hooper; Donald J Phillips; Deborah F Talkington
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

7.  In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.

Authors:  Anke Lührmann; Ursula Deiters; Julia Skokowa; Michaela Hanke; Johannes E Gessner; Peter F Mühlradt; Reinhard Pabst; Thomas Tschernig
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Differential posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans.

Authors:  M J Calcutt; M F Kim; A B Karpas; P F Mühlradt; K S Wise
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.

Authors:  Yohei Takeda; Masahiro Azuma; Kenji Funami; Hiroaki Shime; Misako Matsumoto; Tsukasa Seya
Journal:  Front Immunol       Date:  2018-03-14       Impact factor: 7.561

10.  Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.

Authors:  Takashi Akazawa; Toshimitsu Ohashi; Viskam Wijewardana; Kikuya Sugiura; Norimitsu Inoue
Journal:  Cancer Sci       Date:  2018-04-22       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.